---
document_datetime: 2026-01-20 12:28:42
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/aflunov-epar-all-authorised-presentations_en.pdf
document_name: aflunov-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.927707
conversion_datetime: 2026-01-20 20:29:19.651598
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form      | Route of Administration   | Immediate Packaging        | Content (concentration)   | Pack size              |
|------------------|-------------------|------------|--------------------------|---------------------------|----------------------------|---------------------------|------------------------|
| EU/1/10/658/001  | AFLUNOV           | -- 1       | Suspension for injection | Intramuscular use         | pre-filled syringe (glass) | 0.5 ml                    | 1 pre-filled syringe   |
| EU/1/10/658/002  | AFLUNOV           | -- 1       | Suspension for injection | Intramuscular use         | pre-filled syringe (glass) | 0.5 ml                    | 10 pre-filled syringes |

Adjuvant MF59C.1 containing:

squalene

9.75 milligrams

polysorbate 80

1.175 milligrams

sorbitan trioleate

1.175 milligrams

sodium citrate

0.66 milligrams

citric acid

0.04 milligrams